231 related articles for article (PubMed ID: 12577237)
1. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia R
Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
[TBL] [Abstract][Full Text] [Related]
2. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
3. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
4. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
6. [Cytoprotective effects of amifostine in the treatment of tumors].
Burkon P; Petýrek P; Spurný V
Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
8. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
9. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
Koukourakis MI; Simopoulos C; Minopoulos G; Patlakas G; Polychronidis A; Limberis V; Romanides K; Pitiacoudis M; Manolas C
Clin Cancer Res; 2003 Aug; 9(9):3288-93. PubMed ID: 12960114
[TBL] [Abstract][Full Text] [Related]
10. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
11. Dosing considerations with amifostine: a review of the literature and clinical experience.
Dorr RT; Holmes BC
Semin Oncol; 1999 Apr; 26(2 Suppl 7):108-19. PubMed ID: 10348269
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
Anné PR; Curran WJ
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
[TBL] [Abstract][Full Text] [Related]
13. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Mehta MP
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
[TBL] [Abstract][Full Text] [Related]
14. Amifostine as a radioprotectant.
Gosselin TK; Mautner B
Clin J Oncol Nurs; 2002; 6(3):175-6, 180. PubMed ID: 11998614
[No Abstract] [Full Text] [Related]
15. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
[TBL] [Abstract][Full Text] [Related]
16. Amifostine and hematologic effects.
Sriswasdi C; Jootar S; Giles FJ
J Med Assoc Thai; 2000 Apr; 83(4):374-82. PubMed ID: 10808697
[TBL] [Abstract][Full Text] [Related]
17. A new administration schedule for amifostine as a radioprotector in cancer therapy.
Wagner W; Radmard A; Schönekaes KG
Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
19. [New data on cytoprotection in radiotherapy].
Sauer R; Strnad V
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
[No Abstract] [Full Text] [Related]
20. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
